Expert Interview
Discussing Moonlake Therapeutics' Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS)
Ticker(s): MLTXInstitution: Indiana University School of Medicine
- Chair and associate professor of dermatlogy at Indiana University School of Medicine.
- Currently manages 100 patients with vitligo.
- Previously served as Vice-Chair for Research and Education at Tufts Medical Center, focusing on clinical trials for inflammatory disorders of the skin.
How many patients do you manage with for Hidradenitis Suppurativa?
Added By: wilson_adminOn a scale from 1-10 (10 being extremely excited), how excited are you about sonelokimab in HS?
Added By: wilson_adminHow are HS patients managed in your practice, and what drives your choice between biologics like TNFs, IL-17s, and JAK inhibitors? Do payer mandates (e.g. Humira first) or patient characteristics influence treatment selection and sequencing?
Added By: slingshot_insightsHow do you interpret HiSCR endpoints (50/75), placebo response variability, and lesion counts in trials like Povo and SLK? How does their efficacy compare to real-world use of Humira, Cosentyx, and Bimzelx?
Added By: slingshot_insightsDo nanobodies like Sonelokimab offer real advantages over traditional antibodies? What are your expectations for its efficacy and safety (e.g., candidiasis, suicidal ideation) versus other IL-17s?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
